FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:1273-1275 November 15, 1984 Number 20 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Debate continues on whether aging or estrogen deficiency is the more important determinant of postmenopausal bone loss. We compared 14 women who had undergone oophorectomy during young adulthood, 14 normal perimenopausal women, and 14 normal postmenopausal women (mean ages, 54, 52, and 73 years, respectively; mean duration of estrogen deficiency, 22, 0.3, and 22 years, respectively). Bone mineral density was assessed by single-photon and dual-photon absorptiometry. As compared with the perimenopausal group, the other two groups had significantly lower bone mineral density at the midradius, femoral neck, femoral intertrochanteric area, and lumbar spine (-15 per cent, -25 per cent, -16 per cent, and -23 per cent, respectively, in the oophorectomized group and -18 per cent, -28 per cent, -26 per cent, and -23 per cent, respectively, in the postmenopausal group). Because bone loss in the oophorectomized group (differing from the perimenopausal group in menopausal status but not in age) was almost as great as in the postmenopausal group (differing in both characteristics), we suggest that estrogen deficiency, and not aging, may be the predominant cause of bone loss occurring during the first two decades after natural menopause.

This article has been cited by other articles:

• Rohr, J., Allen, E.G., Charen, K., Giles, J., He, W., Dominguez, C., Sherman, S.L. (2008). Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod 23: 1220-1225 [Abstract] [Full Text]  
• Sowers, M. R., Jannausch, M., McConnell, D., Little, R., Greendale, G. A., Finkelstein, J. S., Neer, R. M., Johnston, J., Ettinger, B. (2006). Hormone Predictors of Bone Mineral Density Changes during the Menopausal Transition. J. Clin. Endocrinol. Metab. 91: 1261-1267 [Abstract] [Full Text]  
• Taveira-DaSilva, A. M., Stylianou, M. P., Hedin, C. J., Hathaway, O., Moss, J. (2005). Bone Mineral Density in Lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 171: 61-67 [Abstract] [Full Text]  
• Sverrisdottir, A., Fornander, T., Jacobsson, H., von Schoultz, E., Rutqvist, L.E. (2004). Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy. JCO 22: 3694-3699 [Abstract] [Full Text]  
• Gennari, L., Masi, L., Merlotti, D., Picariello, L., Falchetti, A., Tanini, A., Mavilia, C., Del Monte, F., Gonnelli, S., Lucani, B., Gennari, C., Brandi, M. L. (2004). A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism. J. Clin. Endocrinol. Metab. 89: 2803-2810 [Abstract] [Full Text]  
• Gennari, L., Merlotti, D., Martini, G., Gonnelli, S., Franci, B., Campagna, S., Lucani, B., Dal Canto, N., Valenti, R., Gennari, C., Nuti, R. (2003). Longitudinal Association between Sex Hormone Levels, Bone Loss, and Bone Turnover in Elderly Men. J. Clin. Endocrinol. Metab. 88: 5327-5333 [Abstract] [Full Text]  
• McDougall, K. E., Perry, M. J., Gibson, R. L., Colley, S. M., Korach, K. S., Tobias, J. H. (2003). Estrogen Receptor-{alpha} Dependency of Estrogen's Stimulatory Action on Cancellous Bone Formation in Male Mice. Endocrinology 144: 1994-1999 [Abstract] [Full Text]  
• McDougall, K. E., Perry, M. J., Gibson, R. L., Bright, J. M., Colley, S. M., Hodgin, J. B., Smithies, O., Tobias, J. H. (2002). Estrogen-induced osteogenesis in intact female mice lacking ERbeta. Am. J. Physiol. Endocrinol. Metab. 283: E817-E823 [Abstract] [Full Text]  
• Palter, S. F., Tavares, A. B., Hourvitz, A., Veldhuis, J. D., Adashi, E. Y. (2001). Are Estrogens of Import to Primate/Human Ovarian Folliculogenesis?. Endocr. Rev. 22: 389-424 [Abstract] [Full Text]  
• Newcomb, P. A., Trentham-Dietz, A., Egan, K. M., Titus-Ernstoff, L., Baron, J. A., Storer, B. E., Willett, W. C., Stampfer, M. J. (2001). Fracture History and Risk of Breast and Endometrial Cancer. Am J Epidemiol 153: 1071-1078 [Abstract] [Full Text]  
• Col, N. F., Hirota, L. K., Orr, R. K., Erban, J. K., Wong, J. B., Lau, J. (2001). Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk. JCO 19: 2357-2363 [Abstract] [Full Text]  
• Rosvold Berntsen, G. K., Fonnebo, V., Tollan, A., Johanne Sogaard, A., Magnus, J. H. (2001). Forearm Bone Mineral Density by Age in 7,620 Men and Women The Tromso Study, a Population-based Study. Am J Epidemiol 153: 465-473 [Abstract] [Full Text]  
• Pfeilschifter, J., Diel, I. J. (2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO 18: 1570-1593 [Abstract] [Full Text]  
• Recker, R. R., Davies, K. M., Dowd, R. M., Heaney, R. P. (1999). The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women: A Randomized, Controlled Trial. ANN INTERN MED 130: 897-904 [Abstract] [Full Text]  
• Moghetti, P., Castello, R., Zamberlan, N., Rossini, M., Gatti, D., Negri, C., Tosi, F., Muggeo, M., Adami, S. (1999). Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist. J. Clin. Endocrinol. Metab. 84: 1250-1254 [Abstract] [Full Text]  
• Janssen, Y. J. H., Hamdy, N. A. T., Frölich, M., Roelfsema, F. (1998). Skeletal Effects of Two Years of Treatment with Low Physiological Doses of Recombinant Human Growth Hormone (GH) in Patients with Adult-Onset GH Deficiency. J. Clin. Endocrinol. Metab. 83: 2143-2148 [Abstract] [Full Text]  
• Erben, R. G., Raith, S., Eberle, J., Stangassinger, M. (1998). Ovariectomy augments B lymphopoiesis and generation of monocyte-macrophage precursors in rat bone marrow. Am. J. Physiol. Endocrinol. Metab. 274: E476-E483 [Abstract] [Full Text]  
• Lea, C. K., Flanagan, A. M. (1998). Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat. Am. J. Physiol. Endocrinol. Metab. 274: E328-E335 [Abstract] [Full Text]  
• Westerlind, K. C., Wronski, T. J., Ritman, E. L., Luo, Z.-P., An, K.-N., Bell, N. H., Turner, R. T. (1997). Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. USA 94: 4199-4204 [Abstract] [Full Text]  
• Schneider, D. L., Barrett-Connor, E. L., Morton, D. J. (1997). Timing of Postmenopausal Estrogen for Optimal Bone Mineral Density: The Rancho Bernardo Study. JAMA 277: 543-547 [Abstract]  
• Kauffman, R. F., Bensch, W. R., Roudebush, R. E., Cole, H. W., Bean, J. S., Phillips, D. L., Monroe, A., Cullinan, G. J., Glasebrook, A. L., Bryant, H. U. (1997). Hypocholesterolemic Activity of Raloxifene (LY139481): Pharmacological Characterization as a Selective Estrogen Receptor Modulator. J. Pharmacol. Exp. Ther. 280: 146-153 [Abstract] [Full Text]  
• Mariotti, A. (1994). Sex Steroid Hormones and Cell Dynamics in the Periodontium. CROBM 5: 27-53 [Abstract] [Full Text]  
• Kleerekoper, M., Brienza, R. S., Schultz, L. R., Johnson, C. C. (1991). Oral Contraceptive Use May Protect Against Low Bone Mass. Arch Intern Med 151: 1971-1976 [Abstract]  
• Kung, A. W. C., Pun, K. K. (1991). Bone Mineral Density in Premenopausal Women Receiving Long-term Physiological Doses of Levothyroxine. JAMA 265: 2688-2691 [Abstract]  
• Naessen, T., Persson, I., Adami, H.-O., Bergstrom, R., Bergkvist, L. (1990). Hormone Replacement Therapy and the Risk for First Hip Fracture: A Prospective, Population-based Cohort Study. ANN INTERN MED 113: 95-103 [Abstract]